
RFK Jr.ãCOVIDã¯ã¯ãã³ã«ããè² å·ããŒãã«ãäœæãã â ã€ãã«ããå€ãã®äººãæªæã«å¯ŸããŠè£åãããã®ã?
å èšäºã¯ãã¡ããã/Click here to read the original article.
ä¿å¥å€§è£RFKãžã¥ãã¢ã¯11æã«COVID-19ã¯ã¯ãã³ã«ãã被害æ¡ä»¶ã®ææ¡ãèšç»ããŠãããåŒè·å£«ãã¡ã¯ãã®åããã¯ã¯ãã³ã§è¢«å®³ãåããæ°å人ãžã®å ¬æ£ãªè£åãžã®æãéãå¯èœæ§ããããšè¿°ã¹ãŠããŸãã
(å ç«¥å¥åº·é²è¡)â ç±³åœä¿å¥é·å®ãããŒãã»Fã»ã±ããã£ã»ãžã¥ãã¢ã¯ãCOVID-19ã¯ã¯ãã³ã§è² å·ãã人ã ãé£éŠæ¿åºããè£åãåãããããªããããªèŠåå¶å®ããã»ã¹ãéå§ããæºåãé²ããŠãããããã¯ã¯ã¯ãã³å·å®³ããã°ã©ã ã«ããããããŸã§ã§æãéèŠãªå€æŽã®äžã€ãšãªãã
é£éŠèŠå¶ã®è°é¡ã«ãããšãç±³åœä¿å¥çŠç¥ç(HHS)ã¯11æã«COVID-19ã¯ã¯ãã³ã®æ£åŒãªãå·å®³ããŒãã«ããèšããèŠåãææ¡ããäºå®ã§ãããã®ææ¡ã¯æçµèŠåãæœè¡ãããåã«ã2027幎åé ãŸã§ç¶ããšäºæ³ããããããªãã¯ã³ã¡ã³ãæéãçµãèŠèŸŒã¿ã§ãã
ã±ããã£ã®ææ¡ã§ã¯ãæ¿åºãã¯ã¯ãã³ãå«ãã«ããŒå¯Ÿè±¡ã®COVID-19察çã«ãã£ãŠåŒãèµ·ãããããšæšå®ãããè² å·ãç¹å®ãã衚ãèšãããã®ã§ãã
è¡šã«æªæãèšèŒããã«ã¯ãã¯ã¯ãã³ãšæªæãçµã³ã€ããã説åŸåããããä¿¡é Œã§ãããæå¹ã§ãå»åŠçãã€ç§åŠç蚌æ ããæ±ããããŸãããŸããã¯ã¯ãã³æ¥çš®åŸã«ãããã®æªæãçºçããªããã°ãªããªãæéãèŠå®ãããŸãã
HHSã¯ãã©ã®æªæãå«ãããå ¬è¡šããŠããŸããã
ããããæ³çå°éå®¶ã¯ãmRNACOVID-19ã¯ã¯ãã³ãšç¹ã«ææ¥æããã³è¥å¹Žæäººç·æ§ã®éã§é¢é£ãææãããŠããå¿çç(mMRI COVID-19ã¯ã¯ãã³ãšé¢é£ããŠãã)ããé£éŠä¿å¥æ©é¢ããã§ã«ãã®é¢é£ãèªããŠãããããæ éã«æ€èšããããšäºæ³ããŠããŸãã
å°éå®¶ã¯ãŸãããã®åããä»ã®ã¯ã¯ãã³å®³ã«å¯Ÿããç£èŠãå éãããå¯èœæ§ããããšèããŠããŸãã
ãCOVID-19ã¯ã¯ãã³ã«ããè² å·ããŒãã«ãäœæããææ¡ã¯çŽ æŽãããã¹ã¿ãŒãã ãšèããŠããŸãããšåŒè·å£«ã®ãã£ãã»ããã³ããŒãæ°ã¯è¿°ã¹ãŸããããããã§ãéåžžã®åã©ãåãã¯ã¯ãã³ã®è£å察象å€å·ã®ãªã¹ããæ¡å€§ããäžæ©ãã€ãªããããšãé¡ã£ãŠããŸãããã®åéãåå®ã«æ¡å€§ãå¿ èŠã§ããã
蚎èšããã£ããã§HHSã¯å·å®³è¡šãäœæããããšã決å®ããã®ã§ãããã?
ãã®ææ¡ã¯ãå ¬å ±æºåã»ç·æ¥æºåæ³(PREPæ³)ã«åºã¥ãæ³åŸã§çŸ©åä»ããããŠããã«ãŠã³ã¿ãŒã¡ãžã£ãŒã»ã±ã¬ãªã¹ãã®äœæãHHSã«åŒ·å¶ããããšãã蚎èšã«ç¶ããã®ã§ãã
ãã®è¡šã¯ãæå®ãããæéå ã«çºçããè£å察象ã®å»ç察çã«ããå·å®³ãæšå®ãããå Žåãç¹å®ããè«æ±è ãééçè£åãåããããããŸãã
蚎èšã§ååã®ãšãªã«ã»ãµã³ãã¯ããã®ããŒãã«ããæ¥µããŠéèŠãã§ããããå¯Ÿææªçœ®ãå·å®³ãåŒãèµ·ããããšããæšå®ããå«ãŸããŠãããšäž»åŒµããŠããŸããããã«ãããé£éŠã®å¯Ÿææªçœ®å·å®³è£åããã°ã©ã (CICP)ãéããŠçµŠä»ãæ±ãã人ã ã®ç«èšŒè²¬ä»»ã軜æžãããŸãã
ãµã³ãã¯ã2021幎ã«ã¢ãã«ãã®COVID-19ã¯ã¯ãã³ã2åæ¥çš®ããåŸãè³çãèŠåã»èŽåã®äœäžãè¡ç®¡æå·ãçºçãããšäž»åŒµããŠããŸãã
蚎ç¶ã«ãããšã圌女ã®è«æ±ã¯2024幎ã«åŽäžãããŸããããªããªããä¿å¥è³æºãµãŒãã¹å±(HRSA)ãã¯ã¯ãã³ãåœŒå¥³ã®æªæãçŽæ¥åŒãèµ·ããããšããæç¢ºãªèšŒæ ãååã§ãªããšçµè«ä»ããããã§ããHRSAã¯HHSã®äžéšéã§ãããCICPãç£ç£ããŠããŸãã
Sampã代衚ããŠèšŽèšãèµ·ãããåŒè·å£«ã¬ã€ã»ãããŒã¬ã¹æ°ã¯ããã®ããŒãã«ãCOVID-19ã¯ã¯ãã³ã«ããè² å·è ã«å ¬æ£ãªæ¯æãã®æ©äŒã確ä¿ã§ãããšè¿°ã¹ãŸããããCICPã¯ãã®å¹æãäžããŠããªããšè¿°ã¹ãŸããã
ãCICPè£åããã°ã©ã ã¯è² å·ãããã¹ãŠã®äººã«ãšã£ãŠãã©ãã¯ããŒã«ã®ãããªãã®ã§ãããšãããŒã¬ã¹ã¯The Defenderã«èªããŸããããåèšã§60ä»¶ã®è«æ±ããæ¯æãããŠããŸãããæ»äº¡ãŸãã¯éå·ã«å¯Ÿããäžå€®å€ã®è³ åéã¯4,300ãã«ã§ããè©æ¬ºã ...ãã®[ææ¡ãããèŠå]ã¯ãç· ãåããéããä»ã®èª°ã§ãå¿åã§ããæãéããŸãã圌ãã¯ä»ãé£éŠè£å€æã«èšŽãããã£ã³ã¹ããããã
ã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã (VAERS)ã«æåºãããCOVID-19ã¯ã¯ãã³æå®³äºè±¡ã«é¢ãã150äžä»¶ä»¥äžã®å ±åã¯ãé£éŠCICPãæ¿åºã®ãé節ãªèº«äœçå·å®³ãã®å®çŸ©ãæºããæ»äº¡ããã³è² å·ã®ã¿ãã«ããŒããŠãããããè£åã®å¯Ÿè±¡å€ã§ãã
ãã¯ã¯ãã³ã«ããå·å®³ã®ããŒãã«ã¯ãããå€ããªãããšãããŒã¬ã¹ã¯è¿°ã¹ããããããããã¯ä»ã®äººã®å©ãã«ãªãã§ãããã圌ã¯ããè¿°ã¹ãã
ã¯ã¯ãã³å·å®³è¡šã®çŽ æŽãããç¹ã¯ãã¯ã¯ãã³æ¥çš®åŸã®æªæã®çºçãŸã§ã«1æ¥ã1é±éã6æ¥ããŸãã¯2é±éã®æéãäžããŠãããããšã§ãããããããŒãã«ã®åœ¹å²ã§ããæªæãæè¡å°ã«ããå Žåãåå ã¯ã¯ã¯ãã³ã«ãããã®ãšæšå®ãããŸããã ããããéèŠãªã®ã§ãã
HHSã¯èšŽèšã«å¯ŸããŠ7æ21æ¥ãŸã§ã«åçããæéããããŸãã
HHSã代衚ããåŒè·å£«ã¯ã³ã¡ã³ãã®èŠè«ã«å¿ããŸããã§ãããHHSãäºä»¶ãã¯ã¯ãã³è¢«å®³ã®è¡šã«ã€ããŠå°ããŠãçããŸããã§ããã
ã¯ã¯ãã³ã«ããå·å®³è£åããã°ã©ã ãšç ç©¶
COVID-19ã¯ã¯ãã³ã¯ã1986幎ã«è°äŒã«ãã£ãŠèšç«ãããæ°å幎ã«ãããç¡é倱è£åå¶åºŠã§ããåœå®¶ã¯ã¯ãã³å·å®³è£åããã°ã©ã (VICP)ããé€å€ãããŠããŸãããã®å¶åºŠã¯ã¯ã¯ãã³ã¡ãŒã«ãŒãéå°ãªèšŽèšããå®ãã€ã€ãæ£åœãªã¯ã¯ãã³ã«ããå·å®³ãåãã人ã ãè£åãåããããããã«ããããã§ãã
代ããã«ãCOVID-19ã¯ã¯ãã³ã«ããå·å®³è«æ±ã¯CICPãéããŠåŠçãããªããã°ãªããŸãããCICPã¯ãããå³ããåºæºãäœãè£åçãæ§èšŽã®æ©äŒã®éãããããšã§æ³çå°éå®¶ãæ£è æè·è ããåºãæ¹å€ãããŠããŸãã
COVID-19ã¯ã¯ãã³ã«ããæå·ã¯ã2024幎ã®å šç±³ç§åŠã»å·¥åŠã»å»åŠã¢ã«ãããŒã®ã¬ãã¥ãŒã§è©äŸ¡ãããçèå ã¯ã¯ãã³æ¥çš®ã«é¢é£ããæ°çŸä»¶ã®ç ç©¶ã調æ»ãããŸããã
VICPã«éç¥ããããã«å§èšããã336ããŒãžã®å ±åæžã¯ãç±³åœã§æ¿èªãŸãã¯æ¿èªããã4çš®é¡ã®COVID-19ã¯ã¯ãã³ããã¡ã€ã¶ãŒãã¢ãã«ãããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³(ã€ã³ã»ã³)ãããããã¯ã¹ã®èšŒæ ãè©äŸ¡ããŸããã
å§å¡äŒã¯ã¯ã¯ãã³é¢é£ã®æå®³äºè±¡ã®å¯èœæ§ã«ã€ããŠ85ã®çµè«ã«éããŸããã20ã®çµè«ã«ååãªèšŒæ ããããšå€æãã€ã€ãå€ãã®ä»ã®å ±åãããç¶æ ã®èšŒæ ã¯å æé¢ä¿ã確ç«ãåçããŸãã¯åŠå®ããã«ã¯äžååã§ãããšå€æããŸããã
ã¬ãã¥ãŒã§ã¯ãç¹å®ã®COVID-19ã¯ã¯ãã³ãšãmRNAã¯ã¯ãã³åŸã®å¿ççãå¿èçããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ã¯ã¯ãã³åŸã®è¡å°æ¿æžå°çå矀ã䌎ãè¡æ çãCOVID-19ã¯ã¯ãã³æ¥çš®åŸã®ã¢ããã£ã©ãã·ãŒãªã©ãããã€ãã®çšãªæå®³äºè±¡ãšã®å æé¢ä¿ãæ¯æãã蚌æ ãèŠã€ãããŸããã
ãŸããäžé©åãªã¯ã¯ãã³æ¥çš®ãè©ã骚ãç¥çµã®æå·ãåŒãèµ·ããå¯èœæ§ããããšãã蚌æ ãçºèŠããŸããã
2020幎ã«ããšãã¹ã¢ã€ã¬ã¹ã§è¡ããããã¡ã€ã¶ãŒã®COVID-19ã¯ã¯ãã³èšåºè©Šéšã«åå ãããã®åŸè£œè¬å€§æã蚎ããã¢ã«ãŒã³ãã³ã®åŒè·å£«ã¢ãŠã°ã¹ãã»ã«ãŒã¯ãããã£ãã§ã³ããŒãçŽã«å¯Ÿããã¯ã¯ãã³ãå åèãèèã®æå·ãåŒãèµ·ããããšèªã£ãã
ã仿¥ã§ãå åèãèèã®åŸéºçã«æ©ãŸãããŠããŸãããšåœŒã¯èªããŸããããåžæ³çã¯èšåºè©Šéšã®èª¿æ»ãéå§ãã¹ãã ãäºä»¶äžã«çºèŠããé èœããããããè£åã¯åžæ³èª¿æ»ã«ãã£ãŠçããã¹ãã§ããã
ãã¡ã€ã¶ãŒã¯ã³ã¡ã³ãã®èŠè«ã«å¿ããŸããã§ããã
ãã¯ã¯ãã³æ¥çš®åŸã®æªæã¯çŸå®çã ââããããã¹ãã ...è£åãããã
COVID-19ã®è² å·ããŒãã«ã®äœæã¯ãã¯ã¯ãã³ã«ãã£ãŠæªæãè² ã£ããšèããäœå人ãã®äººã ã«ãšã£ãŠå€§ããªå€åãããããå¯èœæ§ããããŸããè«æ±è ãèšèŒãããåºæºãæºããã°ããŒãããäºä»¶ãç«èšŒããå¿ èŠããªããªããããå¹çåãè£åãæåŸ ã§ããŸãã
ãã¯ã¯ãã³ã«ããå·å®³ã®æ¡ä»¶ã远å ããããšã«è³æã§ãããããã¯VICPããã°ã©ã ã®ç®çãšæŽåããããšåŒè·å£«ã®ãã€ã±ã«ã»ããŠã æ°ã¯è¿°ã¹ãããã¯ã¯ãã³æ¥çš®åŸã®æªæã¯çŸå®ã®ãã®ã§ãããèªãããè£åãããã¹ãã§ããã
ãã®ææ¡ã¯ãCOVID-19ã¯ã¯ãã³ã®å®å šæ§ãããã¡ã€ã«ããããè°è«ãç¶ãäžã§çºè¡šãããŸãããæ°åååã®æäžã察象ãšããåºç¯ãªèšåºè©Šéšãšæ¿èªåŸã®å®å šæ§ç£èŠã«ãããæ·±å»ãªæå®³äºè±¡ã¯çšã§ããããšãæããã«ãªããŸããã
ããããCOVID-19ã¯ã¯ãã³ã¯ãããŸã§ã®ã¯ã¯ãã³ãããå€ãã®VAERSãžã®å ±åãçã¿åºããŠãããããã¯åäŸã®ãªãèŠæš¡ã®ã¯ã¯ãã³æ¥çš®ãã£ã³ããŒã³ãåçºã®é«ãŸããç·æ¥äœ¿çšèš±å¯ã«ãã矩åå ±å矩åã倧ããããã§ãã
4æããã³ã»ãžã§ã³ãœã³äžé¢è°å¡(å ±åå ã»ãŠã£ã¹ã³ã³ã·ã³å·)ã¯ãç±³åœé£åå»è¬åå±(FDA)ã®é¢ä¿è ãVAERSå ±åãåæããããã«å£ã£ãå®å šä¿¡å·æ€åºæ¹æ³ãæ æã«äœ¿çšããé·å¹Žã®FDAç ç©¶è ã«æ¹è¯ãããããŒã«ã®äœ¿çšãã忢ãããããæç€ºããããšãç€ºãææžãåŒçšããå ±åæžãçºè¡šããŸããã
å ±åæžã¯ãã¯ã¯ãã³ãäžè¬ã«å ±åããŠãããããé節ãªå·å®³ãåŒãèµ·ãããŠããããšãåæ©é¢ãèªèããŠããããšã瀺åããŠããŸãã
ç±³åœçŸç äºé²ç®¡çã»ã³ã¿ãŒ(CDC)ã®V-safe COVID-19ã¯ã¯ãã³ç£èŠã·ã¹ãã ã®æè¿ã®åæã§ã¯ãã¯ã¯ãã³ã«å¯Ÿããçæçãªåå¿ã確èªãããŸãããããããTrialSite Newsã¯ãããæ·±å»ã§é ããé·æçãªæªæãæããããšãã§ããªãã£ããšå ±ããŠããŸãã
6æ26æ¥æç¹ã§ãVAERSã¯COVID-19ã¯ã¯ãã³æ¥çš®åŸã®éå·ã®å ±åã194äžä»¶ããã®ãã¡38,648äººãæ»äº¡ããããšã瀺ããŸããã
è°äŒã¯è¡åãèµ·ããã®ã§ãããã?
HHSã®ææ¡ã¯CICPã®å¹çãåäžãããã®ã§ãããã?
é£éŠã®ã¯ã¯ãã³è¢«å®³è£åã«é¢ãã2åã®èæžãæã€ç ç©¶è ãŠã§ã€ã³ã»ããŒãæ°ã¯ãããã£ãã§ã³ããŒãã«å¯Ÿããè°äŒãã¯ã¯ãã³è¢«å®³è ã®ããã«çŽ30åãã«ãšæšå®ããè³æºãé åããªãã®ã§ã¯ãªãããšæžå¿µããŠããŸãããŸããå€ãã®ã±ãŒã¹ã¯è§£æ±ºã«äœå¹Žããããå¯èœæ§ããããšãè¿°ã¹ãŸããã
ãããããŒãæ°ã¯ãã©ããªå°é£ããã£ãŠãããã®å€§çŸ©ã¯æªæ¥ã«ãšã£ãŠæ¥µããŠéèŠã ãšè¿°ã¹ãŸããã
ãåé¡ã¯ããã®äººãã¡ã«è£åããããã©ããã ãããšåœŒã¯å°ããããæžå¿µã¯ãä»äœãããªããã°ã次ã®ãã³ãããã¯ã®æã«ããã«æªåãããšããããšã§ããã
ã¯ã¯ãã³ãæ¥çš®ã®è åšãåãè² å·ãã忥ãã€ãããã®ããã»ã¹ããŠæ°ã¯ãããã£ãã§ã³ããŒãçŽã«å¯ŸããçŸè¡ã®è£åå¶åºŠã¯æ©èœããŠããªããšèªããŸããã
ãæ®å¿µãªãããçŸè¡ã®èšç»ã¯è€éã§ãè³éã®æ¯æãã«é©ããªãã¹ã±ãžã¥ãŒã«ã§æ§æãããŠããŸãããšã¹ããŠã¯è¿°ã¹ãã
圌ã¯ããã«ããä»ãå ããŸããã
ãã®ã·ã¹ãã ã¯æ¿æ²»åãããããŠãå¥åº·ãå®å šãã€ã³ãã©ãŒã ãã³ã³ã»ã³ããéæ¿ãªèããšèŠãªããã害ã䞻匵ããè ã¯ã¬ã¹ã©ã€ãã£ã³ã°ãããå²ç¬ãããææ¥ãããŠããŸããèªç¥çäžååã®ã¬ãã«ãããããããã®åèŠãå€ãããŸã§ã¯ãçµæžçã»æ¿æ²»çå©çã®åæ¹ã«å¯ŸããŠå³ããæŠããåŸ ã£ãŠãããšç§ã¯èŠãŠããŸãããšã¯ãããæçµçã«ã¯ååããªå€åã«åžæãæã£ãŠããŸãã